HCRT and COVID-19: In addition to COVID-19, orexin A, substance P, bradykinin, and DABK, and the complex interplay between the renin–angiotensin system and the orexinergic system may also have implications for other serious respiratory viral diseases, such as influenza or respiratory syncytial virus.